S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13

MiMedx Group Stock Forecast, Price & News

-0.17 (-2.44%)
(As of 12/3/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
481,400 shs
Average Volume
456,414 shs
Market Capitalization
$763.67 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive MDXG News and Ratings via Email

Sign-up to receive the latest news and ratings for MiMedx Group and its competitors with MarketBeat's FREE daily newsletter.

MiMedx Group logo

About MiMedx Group

MiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. It serves the wound care, burn, surgical, orthopedic, spine, sports medicine, ophthalmic, and dental sectors of healthcare. Its biomaterial platform technologies include AmnioFix and EpiFix, a tissue allografts derived from amnion and chorion layers of human placental membrane; EpiCord and AmnioCord, a tissue allografts derived from umbilical cord tissue, and AmnioFill, a placental connective tissue matri derived from the placental disc and other placental tissue. The company was founded on July 30, 1985 and is headquartered in Marietta, GA.


MIMEDX Announces Speakers for December 7 Investor Day
November 30, 2021 |  finance.yahoo.com
MDXG: Third Quarter Results
November 5, 2021 |  finance.yahoo.com
MIMEDX to Host Virtual Investor Day on December 7, 2021
October 14, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Surgical & medical instruments
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$248.23 million
Book Value
($0.05) per share


Net Income
$-49.28 million
Pretax Margin




Free Float
Market Cap
$763.67 million

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

2.16 out of 5 stars

Medical Sector

435th out of 1,390 stocks

Surgical & Medical Instruments Industry

46th out of 126 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

MiMedx Group (NASDAQ:MDXG) Frequently Asked Questions

Is MiMedx Group a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MiMedx Group in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MiMedx Group stock.
View analyst ratings for MiMedx Group
or view top-rated stocks.

How has MiMedx Group's stock been impacted by Coronavirus?

MiMedx Group's stock was trading at $5.45 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MDXG stock has increased by 25.0% and is now trading at $6.81.
View which stocks have been most impacted by COVID-19

When is MiMedx Group's next earnings date?

MiMedx Group is scheduled to release its next quarterly earnings announcement on Monday, March 14th 2022.
View our earnings forecast for MiMedx Group

How were MiMedx Group's earnings last quarter?

MiMedx Group, Inc. (NASDAQ:MDXG) announced its quarterly earnings data on Tuesday, November, 2nd. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.08) by $0.04. MiMedx Group had a negative trailing twelve-month return on equity of 1,262.51% and a negative net margin of 12.34%. During the same quarter in the previous year, the firm earned ($0.48) EPS.
View MiMedx Group's earnings history

What guidance has MiMedx Group issued on next quarter's earnings?

MiMedx Group updated its FY 2021 earnings guidance on Wednesday, November, 10th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $245 million-$255 million, compared to the consensus revenue estimate of $250.81 million.

What price target have analysts set for MDXG?

2 equities research analysts have issued 1 year price objectives for MiMedx Group's stock. Their forecasts range from $8.50 to $23.00. On average, they expect MiMedx Group's stock price to reach $15.75 in the next year. This suggests a possible upside of 131.3% from the stock's current price.
View analysts' price targets for MiMedx Group
or view top-rated stocks among Wall Street analysts.

Who are MiMedx Group's key executives?

MiMedx Group's management team includes the following people:
  • Timothy R. Wright, Chief Executive Officer & Director
  • Scott M. Turner, Senior Vice President-Operations & Procurement
  • Peter M. Carlson, Chief Financial Officer
  • David H. Mason, Chief Medical Officer
  • Robert Benjamin Stein, Executive Vice President-Research & Development

What is MiMedx Group's stock symbol?

MiMedx Group trades on the NASDAQ under the ticker symbol "MDXG."

Who are MiMedx Group's major shareholders?

MiMedx Group's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.60%), Geode Capital Management LLC (1.49%), Pura Vida Investments LLC (1.14%), Polar Asset Management Partners Inc. (0.71%), Parsons Capital Management Inc. RI (0.66%) and Bank of New York Mellon Corp (0.39%).
View institutional ownership trends for MiMedx Group

Which institutional investors are selling MiMedx Group stock?

MDXG stock was sold by a variety of institutional investors in the last quarter, including RTW Investments LP, Beck Mack & Oliver LLC, NovaPoint Capital LLC, Citigroup Inc., Geode Capital Management LLC, Morgan Stanley, Parsons Capital Management Inc. RI, and California State Teachers Retirement System.
View insider buying and selling activity for MiMedx Group
or view top insider-selling stocks.

Which institutional investors are buying MiMedx Group stock?

MDXG stock was purchased by a variety of institutional investors in the last quarter, including Polar Asset Management Partners Inc., BlackRock Inc., Royal Bank of Canada, Pura Vida Investments LLC, Fisher Asset Management LLC, Millennium Management LLC, Boyd Watterson Asset Management LLC OH, and Next Capital Management LLC.
View insider buying and selling activity for MiMedx Group
or or view top insider-buying stocks.

How do I buy shares of MiMedx Group?

Shares of MDXG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MiMedx Group's stock price today?

One share of MDXG stock can currently be purchased for approximately $6.81.

How much money does MiMedx Group make?

MiMedx Group has a market capitalization of $763.67 million and generates $248.23 million in revenue each year. The company earns $-49.28 million in net income (profit) each year or ($0.33) on an earnings per share basis.

How many employees does MiMedx Group have?

MiMedx Group employs 735 workers across the globe.

What is MiMedx Group's official website?

The official website for MiMedx Group is www.mimedx.com.

Where are MiMedx Group's headquarters?

MiMedx Group is headquartered at 1775 W OAK COMMONS COURT NE, MARIETTA GA, 30062.

How can I contact MiMedx Group?

MiMedx Group's mailing address is 1775 W OAK COMMONS COURT NE, MARIETTA GA, 30062. The company can be reached via phone at (770) 651-9100, via email at [email protected], or via fax at 678-384-6741.

This page was last updated on 12/4/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.